natgillin/translations-raw huggingface dataset:
• you have diabetes 
• če imate sladkorno bolezen.
You may be able to use a ‘spacer' with your inhaler. 
Morda boste inhalator lahko uporabili skupaj z "ustnikom".
Warning: Do not break, puncture or burn the pressurised container, even when apparently empty. 
Opozorilo: Tlačnega vsebnika ne odpirajte, ne predirajte in ne zažigajte, tudi če se zdi prazen.
OUTER CARTON, MULTIPACK - WITH BLUE BOX 
ZUNANJA ŠKATLA SKUPNEGA PAKIRANJA - Z MODRIM OKENCEM
Do not use Bevespi Aerosphere if: 
Ne uporabljajte zdravila Bevespi Aerosphere, če:
How to store Bevespi Aerosphere Contents of the pack and other information Instructions for use 
Shranjevanje zdravila Bevespi Aerosphere Vsebina pakiranja in dodatne informacije Navodila za uporabo zdravila
After IV administration of a 0.2 mg dose of radiolabelled glycopyrronium, 85% of the dose was recovered in urine 48 hours post dose and some of radioactivity was also recovered in bile. 
Po intravenski uporabi 0,2-mg odmerka radioaktivno označenega glikopironija se je 85 % odmerka pojavilo v urinu v 48 urah po odmerku, nekaj radioaktivnosti pa se je pojavilo tudi v žolču.
Before you use Bevespi Aerosphere for the first time Before you use Bevespi Aerosphere for the first time, make sure that the pointer on the dose indicator is pointing to the right of the “120” inhalation mark in the dose indicator display window (See Figure 
Preden prvič uporabite zdravilo Bevespi Aerosphere, se prepričajte, da kazalec na kazalniku odmerka kaže desno od oznake vpihov "120" (v okencu kazalnika odmerka) (glejte sliko 1).
These include medicines for the treatment of: o depression (such as monoamine oxidase inhibitors or tricyclic antidepressants), o bacterial infections (such as erythromycin, clarithromycin, telithromycin), o allergic reactions (anti-histamines). 
Mednje sodijo zdravila, ki jih uporabljamo pri zdravljenju: o depresije (kot so zaviralci monoaminooksidaze ali triciklični antidepresivi), o bakterijskih okužb (kot so eritromicin, klaritromicin in telitromicin), o alergijskih reakcij (antihistaminiki).
Step 6: Let the actuator air-dry overnight (See Figure 17). 
6. korak: Pustite sprožilnik, da se čez noč posuši na zraku (glejte sliko 17).
PINNACLE 4 used TDI. 
V študiji PINNACLE 4 so uporabili TDI.
• you have prostate problems, or difficulty passing urine 
• če imate težave s prostato ali z odvajanjem urina.
Studies evaluating the effect of renal impairment on the pharmacokinetics of glycopyrronium and formoterol have not been conducted. 
Študij za ovrednotenje učinka okvare ledvic na farmakokinetiko glikopironija in formoterola niso izvedli.
You may notice that your heart is beating faster than usual, you feel shaky, you have visual disturbances, have a dry mouth, or have a headache or feel nauseous (sick). 
Morda boste opazili hitrejši srčni utrip kot običajno, občutek tresenja, motnje vida, suha usta, glavobol ali občutek slabosti s siljenjem na bruhanje.
In-vitro studies indicate that formoterol does not inhibit the CYP450 enzymes at therapeutically relevant concentrations. 
Študije in vitro kažejo, da formoterol v terapevtsko pomembnih koncentracijah ne zavira encimov CYP450.
The toxicity observed in studies with the combination of glycopyrronium and formoterol in dogs were associated with the pharmacological actions of formoterol, including effects mainly on the cardiovascular system, consisting of hyperaemia, tachycardia, arrhythmias and myocardial lesions. 
Toksičnost, opažena v študijah s kombinacijo glikopironija in formoterola pri psih, je bila povezana s farmakološkim delovanjem formoterola, vključno z učinki predvsem na srčno-žilni sistem, ki so obsegali hiperemijo, tahikardijo, motnje srčnega ritma in lezije miokarda.
Estimated glomerular filtration rate (eGFR) varied from 30-196 mL/min, representing a range of moderate to no renal impairment. 
Ocenjena hitrost glomerularne filtracije (eGFR) je segala od 30 do 196 ml/min; to ustreza stanju od zmerne okvare ledvic do brez okvare ledvic.
These are known pharmacological manifestations seen after administration of high doses of adrenoceptor agonists. 
To so znani farmakološki učinki po uporabi velikih odmerkov agonistov adrenergičnih receptorjev .
In the airways, it exhibits pharmacological effects through inhibition of the M3 receptor at the smooth muscle leading to bronchodilation. 
V dihalih se njegovi farmakološki učinki kažejo z zavrtjem receptorjev M3 v gladkih mišicah; to povzroči bronhodilatacijo.
The primary metabolism of formoterol is by direct glucuronidation and by O-demethylation followed by conjugation to inactive metabolites. 
Primarna presnova formoterola poteka z neposredno glukuronidacijo in O-demetilacijo, čemur sledi konjugacija neaktivnih presnovkov.
The typical clearance (CL/F) of glycopyrronium was 124 L/h. 
Značilni očistek (CL/F) glikopironija je bil 124 l/h.
The pressurised container should not be broken, punctured or burnt, even when apparently empty. 
Tlačnega vsebnika ne lomite, ne prebadajte in ne sežigajte, tudi če se zdi prazen.
There are no data on the use of Bevespi Aerosphere in pregnant women. 
Podatkov o uporabi zdravila Bevespi Aerosphere pri nosečnicah ni.
• you have low levels of potassium in the blood 
• če imate nizko koncentracijo kalija v krvi.
The clinical development program for Bevespi Aerosphere included three 24-week, randomised, double-blind, placebo-controlled, parallel-group pivotal Phase III studies in 5,433 patients with moderate to very severe COPD (PINNACLE 1, PINNACLE 2 and PINNACLE 4). 
Program kliničnega razvoja zdravila Bevespi Aerosphere je obsegal tri 24-tedenske randomizirane, dvojno slepe, s placebom kontrolirane ključne študije III. faze z vzporednimi skupinami pri 5433 bolnikih z zmerno do zelo hudo KOPB (PINNACLE 1, PINNACLE 2 in PINNACLE 4).
Please read the instructions for use at the end of this leaflet. 
Preberite navodila za uporabo zdravila na hrbtni strani tega navodila za uporabo.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking Bevespi Aerosphere. 
Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom ali farmacevtom, preden vzamete zdravilo Bevespi Aerosphere.
• you have thyroid gland problems (called ‘thyrotoxicosis') 
• če imate težave z žlezo ščitnico (imenovane "tirotoksikoza").
In-vitro glycopyrronium is a substrate for the renal transporters OCT2 and MATE1/2K. 
In vitro je glikopironij substrat ledvičnih prenašalcev OCT2 in MATE1/2K.
However, because formoterol is primarily eliminated via hepatic metabolism, an increased exposure can be expected in patients with severe liver impairment. 
Toda, ker se formoterol v prvi vrsti odstrani s presnovo v jetrih, je pri bolnikih s hudo okvaro jeter mogoče pričakovati večjo izpostavljenost.
Steady state is achieved within 2-3 days of repeated dosing of Bevespi Aerosphere, and the extent of exposure is approximately 2.3 times and 1.5 times higher than after the first dose, for glycopyrronium and formoterol, respectively. 
Stanje dinamičnega ravnovesja je doseženo v 2 do 3 dneh ponavljajoče se uporabe zdravila Bevespi Aerosphere in obseg izpostavljenosti je v primerjavi s tisto po prvem odmerku približno 2,3-krat večji za glikopironij in približno 1,5-krat večji za formoterol.
Figure 14 Step 1: Take the pressurised container out of the actuator (See Figure 15). 
Slika 14 1. korak: Vzemite tlačni vsebnik iz sprožilnika (glejte sliko 15).
Hypokalaemia β2-adrenergic agonists may produce significant hypokalaemia, which may increase the susceptibility to cardiac arrhythmias. 
Agonisti adrenergičnih receptorjev β2 lahko povzročijo pomembno hipokaliemijo, ta pa lahko poveča dovzetnost za motnje srčnega ritma.
Following inhaled administration of Bevespi Aerosphere in subjects with COPD, glycopyrronium Cmax occurred at approximately 5 minutes, and formoterol Cmax occurred within 20 to 60 minutes. 
Po inhaliranju zdravila Bevespi Aerosphere je bila pri preiskovancih s KOPB Cmax glikopironija dosežena v približno 5 minutah in Cmax formoterola v približno 20 do 60 minutah.
Bevespi Aerosphere delivers the active ingredients directly to the airways in your lungs as you breathe in. 
Zdravilo Bevespi Aerosphere odda učinkovini neposredno v dihalne poti v pljučih, ko vdihnete.
The systemic exposure (AUC0-12) in subjects with COPD with moderate-severe renal impairment (eGFR of 30-45 mL/min) is approximately 30% higher for glycopyrronium compared to subjects with COPD with normal renal function (eGFR of >90 mL/min). 
Sistemska izpostavljenost (AUC0-12) glikopironiju je pri preiskovancih s KOPB in zmerno hudo okvaro ledvic (eGFR 30-45 ml/min) približno 30 % večja kot pri preiskovancih s KOPB in normalnim delovanjem ledvic (eGFR > 90 ml/min).
Following inhalation of the glycopyrronium and formoterol combination, the pharmacokinetics of each component was similar to those observed when each active substance was administered separately. 
Po inhaliranju kombinacije glikopironija in formoterola je bila farmakokinetika vsake posamezne učinkovine podobna kot med uporabo vsake učinkovine posamezno.
Write the date the pouch is opened on the inhaler label in the space provided. 
Datum odprtja vrečke vpišite na predvideni prostor na nalepki inhalatorja.
Dose indicator 
Kazalnik odmerka
Since glycopyrronium is eliminated mainly by the renal route, drug interaction could potentially occur with medicinal products affecting renal excretion mechanisms. 
Ker se glikopironij izloča predvsem skozi ledvice, bi se morda lahko pojavila medsebojna delovanja z zdravili, ki vplivajo na mehanizem izločanja skozi ledvice.
Step 8: Re-prime your Bevespi Aerosphere inhaler after each cleaning. 
8. korak: Po vsakem čiščenju inhalatorja Bevespi Aerosphere znova opravite osnovno pripravo.
• The colour in the dose indicator display window will change to red, as shown in the shaded area, when there are only 20 puffs of medicine left in your inhaler (See Figure 2d). 
• Ko bo v inhalatorju preostalo le še 20 vpihov zdravila, se bo barva okenca kazalnika odmerka spremenila v rdečo, kot je prikazano na zasenčeni površini (glejte sliko 2d).
These include: o corticosteroids that you take by mouth (such as prednisolone), o diuretics (such as furosemide or hydrochlorothiazide) used for high blood pressure, o some medicines used to treat breathing conditions called methylxanthines (such as theophylline); 
Med takšnimi so: o kortikosteroidi, ki jih zaužijete (peroralni kortikosteroidi), na primer prednizolon, o diuretiki (na primer furosemid ali hidroklorotiazid), ki jih uporabljamo pri zvišanem krvnem tlaku, o nekatera zdravila, imenovana metilksantini, ki se uporabljajo za zdravljenje težav z dihanjem (na primer teofilin).
β-adrenergic blockers β-adrenergic blockers (including eye drops) can weaken or inhibit the effect of β2-adrenergic agonists, such as formoterol. 
Blokatorji adrenergičnih receptorjev β (vključno s kapljicami za oči) lahko zmanjšajo ali zavirajo učinek agonistov adrenergičnih receptorjev β2, kot je formoterol.
If you have used more Bevespi Aerosphere than you should, talk to a doctor or pharmacist immediately. 
Če ste uporabili več zdravila Bevespi Aerosphere, kot bi smeli, se takoj posvetujte z zdravnikom ali farmacevtom.
Although no formal in-vivo drug interaction studies have been performed with Bevespi Aerosphere, studies indicate no clinical evidence of interactions when used concomitantly with other COPD medicinal products including short-acting β2-adrenergic bronchodilators, methylxanthines, and oral and inhaled steroids. 
Z zdravilom Bevespi Aerosphere sicer niso izvedli formalnih študij medsebojnega delovanja zdravil in vivo, vendar študije niso pokazale kliničnih znakov medsebojnih delovanj med sočasno uporabo z drugimi zdravili za KOPB, vključno s kratkodelujočimi β2-adrenergičnimi bronhodilatatorji, metilksantini ter peroralnimi in inhalacijskimi steroidi.
Renal function was found not to affect exposure to formoterol. 
Delovanje ledvic ne vpliva na izpostavljenost formoterolu.
Bevespi Aerosphere is used regularly for long-term treatment of COPD. 
Zdravilo Bevespi Aerosphere se uporablja redno za dolgotrajno zdravljenje KOPB.
Bevespi Aerosphere is not indicated for the treatment of acute episodes of bronchospasm, i.e. as a rescue therapy. 
Zdravilo Bevespi Aerosphere ni indicirano za zdravljenje akutnih napadov bronhospazma, tj. ni indicirano kot rešilno zdravilo.
What Bevespi Aerosphere is and what it is used for 
Kaj je zdravilo Bevespi Aerosphere in za kaj ga uporabljamo
There are no relevant data on the use of Bevespi Aerosphere in patients with severe hepatic impairment and the medicinal product should be used with caution in these patients (see sections 4.4 and 5.2). 
O uporabi zdravila Bevespi Aerosphere pri bolnikih s hudo okvaro jeter ni ustreznih podatkov in pri takšnih bolnikih je treba to zdravilo uporabljati previdno (glejte poglavji 4.4 in 5.2).
Caution should also be exercised in patients with thyrotoxicosis or known or suspected prolongation of the QTc interval (see section 4.5). 
Prav tako je previdnost potrebna pri bolnikih s tirotoksikozo ali znanim podaljšanjem intervala QTc ali sumom nanj (glejte poglavje 4.5).
The pharmacokinetics of glycopyrronium was best described by a two-compartment disposition model with first-order absorption and linear elimination. 
Farmakokinetiko glikopironija je najbolje opisal dvoprostorni model odstranjevanja z absorpcijo prvega reda in linearnim izločanjem.
As a consequence of the differential density of muscarinic receptors and β2-adrenoceptors in the central and peripheral airways of the lung, muscarinic antagonists are more effective in relaxing central airways, and β2-adrenergic agonists are more effective in relaxing peripheral airways; relaxation of both central and peripheral airways with combination treatment may contribute to its beneficial effects on lung function. 
Zaradi različne gostote muskarinskih receptorjev in adrenergičnih receptorjev β2 med osrednjimi in perifernimi dihalnimi potmi v pljučih, muskarinski antagonisti učinkoviteje sproščajo osrednje dihalne poti in adrenergični receptorji β2 učinkoviteje sproščajo periferne dihalne poti.
Bevespi Aerosphere should not be used to treat asthma. 
Zdravila Bevespi Aerosphere se ne sme uporabljati za zdravljenje astme.
When the patient inhales through the mouthpiece at the same time as actuating the inhaler, the substance will follow the inspired air into the airways. 
Če bolnik hkrati s sprožitvijo inhalatorja inhalira skozi ustnik, sproščena suspenzija sledi vdihanemu zraku v dihala.
Peak FEV1 (ml) 
Najvišji FEV1 (ml)
If you do not use your Bevespi Aerosphere for more than 7 days or if exposed to low temperatures or is dropped: 
Če inhalatorja Bevespi Aerosphere ne uporabljate več kot 7 dni, če je izpostavljen nizki temperaturi ali če vam kam pade:
Before you use Bevespi Aerosphere for the first time, you must prime the inhaler. 
Preden inhalator Bevespi Aerosphere prvič uporabite, morate opraviti njegovo osnovno pripravo.
If you are not sure of how to use Bevespi Aerosphere, contact your doctor or pharmacist. 
Če niste prepričani, kako uporabiti zdravilo Bevespi Aerosphere, se posvetujte z zdravnikom ali farmacevtom.
There were no major differences in total systemic exposure (AUC) for both compounds between healthy Japanese and Western subjects. 
Med zdravimi japonskimi in zahodnimi preiskovanci ni bilo večjih razlik v celotni sistemski izpostavljenosti (AUC) ne za eno ne za drugo učinkovino.
If you do not use your Bevespi Aerosphere for more than 7 days, or if the inhaler is exposed to low temperatures or has been dropped, you will need to re-prime it before use. 
Če inhalatorja Bevespi Aerosphere ne uporabite več kot 7 dni, če je izpostavljen nizki temperaturi ali vam je kam padel, ga boste morali pred uporabo znova pripraviti.
• Not use the inhaler if the drying agent, which is inside the foil pouch, has leaked out of its packet. 
• Naj inhalatorja ne uporabi, če se je sušilno sredstvo, ki je v vrečki iz folije, izteklo iz svojega ovoja.
Inhalation of high doses of β2-adrenergic agonists may produce increases in plasma glucose. 
Inhaliranje velikih odmerkov agonistov adrenergičnih receptorjev β2 lahko zveča koncentracijo glukoze v plazmi.
Administration of Bevespi Aerosphere to women who are breast-feeding should only be considered if the expected benefit to the mother is greater than any possible risk to the infant (see section 5.3). 
Uporaba zdravila Bevespi Aerosphere pride pri doječih ženskah v poštev le v primeru, da je pričakovana korist za mater večja od vsakega možnega tveganja za dojenčka (glejte poglavje 5.3).
CYP2D6 was found to be the predominant enzyme involved in the metabolism of glycopyrronium. 
CYP2D6 je glavni encim, ki sodeluje v presnovi glikopironija.
Patients who find it difficult to co-ordinate actuation with inspiration of breath may use Bevespi Aerosphere with a spacer to ensure proper administration of the product. 
Bolniki, ki težko uskladijo sprožitev z vdihom, lahko uporabijo zdravilo Bevespi Aerosphere z ustnikom za zagotovitev ustreznega dajanja zdravila.
Cardiac arrhythmias (atrial fibrillation, supraventricular tachycardia, and extrasystoles) 
Srčne bolezni tahikardija palpitacije motnje srčnega ritma (atrijska fibrilacija, supraventrikularna tahikardija in ekstrasistole)
Figure 17 Step 7: When the actuator is dry, gently press the pressurised container down in the actuator (See Figure 18). 
Slika 17 7. korak: Ko je sprožilnik suh, vanj previdno potisnite tlačni vsebnik (glejte sliko 18).
What you need to know before you use Bevespi Aerosphere 
Kaj morate vedeti, preden boste uporabili zdravilo Bevespi Aerosphere
Figure 2b 110 puffs 
Slika 2b 110 vpihov
The dose indicator display window shows how many puffs of medicine you have left. 
Okence kazalnika odmerka kaže, koliko vpihov zdravila je še preostalo v inhalatorju.
Musculoskeletal and connective tissue disorders 
Bolezni mišično-skeletnega sistema in vezivnega tkiva mišični spazmi pogosti
Bevespi Aerosphere is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD) (see section 5.1). 
Zdravilo Bevespi Aerosphere je indicirano kot vzdrževalno bronhodilatacijsko zdravljenje za olajšanje simptomov pri odraslih bolnikih s kronično obstruktivno pljučno boleznijo (KOPB) (glejte poglavje 5.1).
No evidence of carcinogenicity was seen in 2-year studies in rats and mice. 
V dveletnih študijah na podganah in miših niso ugotovili znakov karcinogenosti.
Single-dose studies in humans found that very small amounts of glycopyrronium passed the placental barrier. 
Študije enkratnih odmerkov pri človeku so pokazale zelo majhno prehajanje glikopironija skozi placentno pregrado.
Bevespi Aerosphere should be used with caution in patients with severe cardiovascular disorders, such as ischaemic heart disease, tachyarrhythmias or severe heart failure. 
Zdravilo Bevespi Aerosphere je treba previdno uporabljati pri bolnikih s hudimi srčno-žilnimi boleznimi, na primer z ishemično boleznijo srca, tahikardnimi motnjami srčnega ritma ali hudim srčnim popuščanjem.
Bevespi Aerosphere contains two bronchodilators: glycopyrronium a long-acting muscarinic antagonist (also referred to as an anticholinergic) and formoterol a long-acting β2-adrenergic agonist with a rapid onset of action. 
Zdravilo Bevespi Aerosphere vsebuje dva bronhodilatatorja: dolgodelujoč muskarinski antagonist (imenovan tudi antiholinergik) glikopironij in dolgodelujoč agonist adrenergičnih receptorjev β2 s hitrim začetkom delovanja formoterol.
The use of Bevespi Aerosphere with the Aerochamber Plus Flow-Vu spacer in COPD patients increased the total systemic exposure to glycopyrronium (as measured by AUC0-12) by 16% while formoterol exposure was unchanged. 
Uporaba zdravila Bevespi Aerosphere z ustnikom Aerochamber Plus Flow-Vu je pri bolnikih s KOPB povečala celotno sistemsko izpostavljenost glikopironiju (merjeno z AUC0-12) za 16 %, izpostavljenost formoterolu pa se ni spremenila.
Animal reproduction studies with formoterol have shown a slightly reduced fertility in male rats at high systemic exposure and implantation losses, as well as decreased early postnatal survival and birth weight at considerably higher systemic exposures than those reached during clinical use. 
Študije vpliva na sposobnost razmnoževanja na živalih so s formoterolom pokazale rahlo zmanjšano plodnost samcev ob veliki sistemski izpostavljenosti ter implantacijske izgube, pa tudi manjše zgodnje postnatalno preživetje in porodno telesno maso ob bistveno večjih sistemskih izpostavljenostih, kakor so dosežene med klinično uporabo.
Multipack containing 3 inhalers each with 120 actuations. 
Skupno pakiranje, ki vsebuje 3 inhalatorje, vsak s 120 sprožitvami.
Using your Bevespi Aerosphere inhaler: Step 1: Remove the cap from the mouthpiece (See Figure 6). 
Uporaba inhalatorja Bevespi Aerosphere: 1. korak: Odstranite pokrovček z ustnika (glejte sliko 6).
Carton containing 1 inhaler with 120 actuations. 
Škatla, ki vsebuje 1 inhalator s 120 sprožitvami.
The excretion of formoterol was studied in six healthy subjects following simultaneous administration of radiolabelled formoterol via the oral and IV routes. 
Izločanje formoterola so raziskali pri šestih zdravih preiskovancih po sočasni peroralni in intravenski uporabi radioaktivno označenega formoterola.
Glycopyrronium did not cause any adverse effects on fertility in rats. 
Pri podganah glikopironij ni povzročal neželenih učinkov na plodnost.
Bevespi Aerosphere comes as a pressurised container with a dose indicator, supplied with a white plastic actuator body and mouthpiece (see Figure 1 of the Instructions for Use at the end of this leaflet). 
Zdravilo Bevespi Aerosphere je na voljo v tlačnem vsebniku s kazalnikom odmerka, opremljenim z belim plastičnim telesom sprožilnika in ustnikom (glejte sliko 1 v "Navodilih za uporabo zdravila" na koncu teh navodil za uporabo).
Step 3: Hold the inhaler with the mouthpiece pointing towards you and breathe out as fully as you comfortably can through your mouth (See Figure 8). 
Slika 7 3. korak: Držite inhalator z ustnikom obrnjenim proti sebi in skozi usta izdihnite tako globoko, kot lahko, ne da bi vam bilo neprijetno (glejte sliko 8).
SIDE VIEW 
POGLED OD STRANI
Clinical drug-drug interaction studies have not been conducted with Bevespi Aerosphere, however, the potential for metabolic interactions is considered to be low based on in-vitro studies (see section 5.2). 
Kliničnih študij medsebojnega delovanja zdravil z zdravilom Bevespi Aerosphere niso izvedli, toda glede na študije in vitro je možnost presnovnih medsebojnih delovanj majhna (glejte poglavje 5.2).
Drug-induced hypokalaemia 
Z zdravilom povzročena hipokaliemija
A population pharmacokinetic analysis of formoterol was performed based on data collected in a total of 437 subjects with COPD. 
Populacijska farmakokinetična analiza formoterola je zajela podatke skupno 437 preiskovancev s KOPB.
Do not clean the pressurised container or let it get wet. 
Tlačnega vsebnika ne čistite in pazite, da se ne zmoči.
Immune system disorders Hypersensitivity reactions including rash and pruritus 
Bolezni imunskega sistema preobčutljivostne reakcije vključno z izpuščajem in srbenjem občasni
CARTON - SINGLE INHALER 
ŠKATLA - EN INHALATOR
If you have any further questions on the use of this medicine, talk to your doctor or pharmacist. 
Če imate dodatna vprašanja o uporabi zdravila, se posvetujte z zdravnikom ali farmacevtom.
Step 2: Take the cap off the mouthpiece. 
2. korak: Snemite pokrovček z ustnika.
If you use more Bevespi Aerosphere than you should 
Če ste uporabili večji odmerek zdravila Bevespi Aerosphere, kot bi smeli